1. Home
  2. Stocks
  3. Bafnaph Share Price

Bafna Pharmaceuticals Share Price

Pharmaceuticals Small Cap

₹79.05 -2.71 (-3.31%)

05 Nov, 2024 16:51

SIP TrendupStart SIP in BAFNAPH

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹79
  • High
  • ₹82
  • 52 Week Low
  • ₹73
  • 52 Week High
  • ₹113
  • Open Price₹82
  • Previous Close₹82
  • Volume597

Investment Returns

  • Over 1 Month -6.22%
  • Over 3 Month -8.56%
  • Over 6 Month -24.32%
  • Over 1 Year -6.73%
SIP Lightning

Smart Investing Starts Here Start SIP with Bafna Pharmaceuticals for Steady Growth!

Bafna Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 684.2
  • PEG Ratio
  • -7
  • Market Cap Cr
  • 187
  • P/B Ratio
  • 2.3
  • Average True Range
  • 3.78
  • EPS
  • 3.1
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.56
  • RSI
  • 52
  • MFI
  • 45.88

Bafna Pharmaceuticals Financial

IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations33.2941.4028.4440.6841.95
Total Income From Operations33.2941.4028.4440.6841.95
P/L Before Interest, Excpt. Items & Tax0.272.13-2.372.926.95
P/L Before Exceptional Items & Tax-0.381.46-2.942.486.35
P/L After Tax from Ordinary Activities-0.721.46-2.942.486.35
Net Profit/Loss For the Period-0.721.46-2.942.486.35
IndicatorMar 24Mar 23
Revenue From Operations [Gross]150.94114.05
Revenue From Operations [Net]150.94114.05
Total Operating Revenues152.47115.35
Total Revenue155.99118.62
Total Expenses148.64107.01
Profit/Loss Before Tax7.3511.62
Profit/Loss For The Period7.3511.34
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity9.484.95
Net Cash Used In Investing Activity-15.05-7.49
Net Cash Used in Finance Activity-0.8510.18
Net Inc/Dec In Cash And Equivalent-6.417.64
Cash And Equivalent End Of Year1.407.81
IndicatorMar 24Mar 23
Total Share Capital23.6623.66
Total Non-Current Liabilities12.769.65
Total Current Liabilities54.0846.48
Total Capital And Liabilities147.68129.58
Total Non-Current Assets53.2142.27
Total Current Assets94.4787.31
Total Assets147.68129.58
Indicator20242023
EBIT Margin (%)6.3211.83
Return On Capital Employed (%)10.2916.42
Return On Equity (%)9.0815.43
Long Term Debt To Equity (%)13.3011.48
Book Value/Share (INR)34.1731.05
IndicatorMar 20Dec 19Sep 19Jun 19Sep 18
Net Sales/Income from operations13.1310.9311.576.858.84
Total Income From Operations13.1310.9311.576.858.84
P/L Before Interest, Excpt. Items & Tax3.05-0.75-0.51-3.58-0.60
P/L Before Exceptional Items & Tax3.02-0.65-0.55-3.71-1.22
P/L After Tax from Ordinary Activities0.60-22.33-0.59-2.13-1.28
Net Profit/Loss For the Period0.60-22.33-0.59-2.13-1.28
IndicatorMar 20Mar 19
Revenue From Operations [Gross]41.3943.36
Revenue From Operations [Net]41.3943.36
Total Operating Revenues42.4743.36
Total Revenue42.7344.01
Total Expenses44.6162.31
Profit/Loss Before Tax-24.44-17.28
Profit/Loss For The Period-24.44-18.35
IndicatorMar 20Mar 19
Net CashFlow - Operating Activity-34.31-1.79
Net Cash Used In Investing Activity32.7714.93
Net Cash Used in Finance Activity7.30-13.38
Net Inc/Dec In Cash And Equivalent5.77-0.24
Cash And Equivalent End Of Year8.482.71
IndicatorMar 20Mar 19
Total Share Capital2.3723.66
Total Non-Current Liabilities3.0229.80
Total Current Liabilities17.1070.82
Total Capital And Liabilities71.31119.47
Total Non-Current Assets35.2271.00
Total Current Assets36.1048.47
Total Assets71.31119.47
Indicator20242023
EBIT Margin (%)6.3211.83
Return On Capital Employed (%)10.2916.42
Return On Equity (%)9.0815.43
Long Term Debt To Equity (%)13.3011.48
Book Value/Share (INR)34.1731.05

Bafna Pharmaceuticals Technicals

EMA & SMA

Current Price
₹79.05
-2.71 (-3.31%)
pointer
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 16
  • 20 Day
  • ₹80.71
  • 50 Day
  • ₹81.69
  • 100 Day
  • ₹83.47
  • 200 Day
  • ₹86.52

Resistance and Support

81.09 Pivot Speed
  • R3 88.17
  • R2 85.59
  • R1 83.67
  • S1 79.17
  • S2 76.59
  • S3 74.67

Is Bafna Pharmaceuticals Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Bafna Pharmaceuticals has an operating revenue of Rs. 143.80 Cr. on a trailing 12-month basis. An annual revenue growth of 32% is outstanding, Pre-tax margin of 5% is okay, ROE of 9% is fair but needs improvement. The company has a reasonable debt to equity of 13%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 9 which is a POOR score indicating inconsistency in earnings, a RS Rating of 17 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 32 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Bafna Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-11 Quarterly Results
2024-08-13 Quarterly Results
2024-05-29 Audited Results
2024-02-12 Quarterly Results
2023-11-09 Quarterly Results

Bafna Pharmaceuticals F&O

Bafna Pharmaceuticals Shareholding Pattern

88.3%
7.69%
4.01%
  • NSE Symbol
  • BAFNAPH
  • BSE Symbol
  • 532989
  • ISIN
  • INE878I01022

Bafna Pharmaceuticals FAQs

Bafna Pharmaceuticals share price is ₹79 As on 05 November, 2024 | 16:37

The Market Cap of Bafna Pharmaceuticals is ₹187 Cr As on 05 November, 2024 | 16:37

The P/E ratio of Bafna Pharmaceuticals is 684.2 As on 05 November, 2024 | 16:37

The PB ratio of Bafna Pharmaceuticals is 2.3 As on 05 November, 2024 | 16:37

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.